文献速递肿瘤 PET/CT核素与放射性配体治疗

摩尔活度、注射质量与PARP靶向放射性示踪剂[18F]olaparib在胶质瘤小鼠模型中摄取的相关性

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma.
PubMed 文献 · EJNMMI Res · 2022-10-09

该研究在两种皮下人胶质母细胞瘤异种移植模型中系统改变[18F]olaparib的摩尔活度(1-320 GBq/μmol)与注射质量(0.04-8.0 μg),评估对肿瘤及正常组织摄取的影响。结果显示肿瘤摄取取决于注射质量而非摩尔活度,注射1 μg时肿瘤摄取最高(达6.9 ± 1.3%ID/g),过高或过低注射质量均降低相对肿瘤摄取(P < 0.05)。作者认为中等注射质量的PARP抑制剂类放射性药物可能改善相对肿瘤摄取及肿瘤/本底比。

要点

  • 肿瘤摄取取决于[TotalF]olaparib注射质量而非摩尔活度。
  • 注射1 μg时肿瘤摄取最高,达6.9 ± 1.3%ID/g。
  • 过高或过低注射质量均降低相对肿瘤摄取(P < 0.05)。

核心结论

  • [TotalF]olaparib的注射质量对肿瘤摄取有显著影响。
  • 中等注射质量的PARP抑制剂类放射性药物可能改善相对肿瘤摄取及肿瘤/本底比,用于癌症诊断和放射性核素治疗。

研究设计与样本

  • 在U251MG和U87MG两种皮下人胶质母细胞瘤异种移植模型中进行体外细胞实验与体内小鼠实验。
  • 给予[TotalF]olaparib,注射质量范围0.04-8.0 μg,摩尔活度范围1-320 GBq/μmol。

主要发现

  • 两种模型均显示[18F]olaparib的选择性摄取。
  • 肿瘤摄取依赖[TotalF]olaparib注射质量(μg)而非摩尔活度。
  • 注射质量1 μg时肿瘤摄取最高,达6.9 ± 1.3%ID/g,与摩尔活度无关。
  • 较低和较高注射质量均导致相对肿瘤摄取(%ID/g)降低(P < 0.05)。
  • U87MG异种移植瘤切片离体分析显示[18F]olaparib瘤内摄取异质性与PARP1表达相关;给予[TotalF]olaparib(> 0.5 μg)后观察到PARP1-3表达显著上调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue. Hence, the injected mass, molar activity and potential pharmacological effects are important considerations for the use of radiolabelled PARP inhibitors for diagnostic and radionuclide therapeutic applications. Here, we performed a systematic evaluation by varying the molar activity of [18F]olaparib and the injected mass of [TotalF]olaparib to investigate the effects on tumour and normal tissue uptake in two subcutaneous human glioblastoma xenograft models. METHODS: [18F]Olaparib uptake was evaluated in the human glioblastoma models: in vitro on U251MG and U87MG cell lines, and in vivo on tumour xenograft-bearing mice, after administration of [TotalF]olaparib (varying injected mass: 0.04-8.0 µg, and molar activity: 1-320 GBq/μmol). RESULTS: Selective uptake of [18F]olaparib was demonstrated in both models. Tumour uptake was found to be dependent on the injected mass of [TotalF]olaparib (µg) but not the molar activity. An injected mass of 1 μg resulted in the highest tumour uptake (up to 6.9 ± 1.3%ID/g), independent of the molar activity. In comparison, both the lower and higher injected masses of [TotalF]olaparib resulted in lower relative tumour uptake (%ID/g; P < 0.05). Ex vivo analysis of U87MG xenograft sections showed that the heterogeneity in [18F]olaparib intratumoural uptake correlated with PARP1 expression. Substantial upregulation of PARP1-3 expression was observed after administration of [TotalF]olaparib (> 0.5 µg). CONCLUSION: Our findings show that the injected mass of [TotalF]olaparib has significant effects on tumour uptake. Moderate injected masses of PARP inhibitor-derived radiopharmaceuticals may lead to improved relative tumour uptake and tumour-to-background ratio for cancer diagnosis and radionuclide therapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chan CY, Hopkins SL, Guibbal F, et al. Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma. EJNMMI Res. 2022. PMID: 36210377. doi:10.1186/s13550-022-00940-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。